Clinical Trial

DBV Technologies Announces Resignation of Board Member

Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –…

3 months ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported…

3 months ago

Genflow Strengthens IP Portfolio

Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH LONDON, UK / ACCESS Newswire…

3 months ago

National Multiple Sclerosis Society Leads the Way in Making it Easier to Diagnose MS

Updates to McDonald Diagnostic Criteria for MS published NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for…

3 months ago

HeartcoR Solutions Expands Suite of Remote Patient Monitoring Devices, Creating a One-Stop Shop for Clinical Trial Partners

The addition of Blue Spark Technologies, Inc. and QT Medical as device partners signals exciting growth for HeartcoR Solutions as…

3 months ago

myTomorrows Expands AI Capabilities to Support Clinical Trial Sites, Streamline Trial Recruitment and Strengthen Site Workflows

The new site solution enables centralized referral management, real-time trial updates and enhanced physician communication to improve patient retention for…

3 months ago

RealTime eClinical Solutions Wins Dual Honors for Innovation and Marketing in the 2025 Clinical Trials Arena Excellence Awards

SAN ANTONIO, Sept. 18, 2025 /PRNewswire/ -- We are proud to announce that RealTime eClinical Solutions has won the Innovation…

3 months ago

ForCast Orthopedics and KORU Medical Systems Announce Agreement for Novel Antibiotic Infusion Therapy

DENVER, CO AND MAHWAH, NJ / ACCESS Newswire / September 18, 2025 / ForCast Orthopedics, Inc. and KORU Medical Systems,…

3 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a…

3 months ago

Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents

Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the…

3 months ago